<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        21-249-10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2010
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ALENDOCAN 70 MG TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ALENDRONIC ACID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        70
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        18.7
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APOTEX" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M05BA04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>ALENDOCAN is the product name for the substance alendronate sodium available <strong>only on prescription </strong>from your physician. Alendronate sodium is a member of a class of non-hormonal drugs called bisphosphonates.</p><p>&nbsp;</p><p>Your physician has prescribed ALENDOCAN because you have a disease known as osteoporosis. ALENDOCAN helps to rebuild bone. This will help prevent you from developing fractures.</p><p>&nbsp;</p><p>Since it is not known how long ALENDOCAN should be continued for osteoporosis, you should discuss the need to stay on this medication with your doctor regularly to determine if ALENDOCAN is still right for you.</p><p>&nbsp;</p><p>Bone undergoes a normal process of rebuilding that occurs continuously throughout your skeleton. &nbsp;First, old bone is removed (resorbed), and then new bone is laid down (formed). This balanced process of resorbing and forming bone keeps your skeleton healthy and strong.</p><p>&nbsp;</p><p>Osteoporosis is a thinning and weakening of the bones. It is common in women after menopause and may also occur in men.</p><p>&nbsp;</p><p>Osteoporosis often occurs in women several years after the menopause, which occurs when the ovaries stop producing the female hormone, estrogen, or are removed (which&nbsp; may occur, for example, at the time of a hysterectomy). The earlier a woman reaches the menopause, the greater the risk of osteoporosis. Osteoporosis can also occur in men due to several causes, including aging and/or a low level of the male hormone, testosterone. In all instances, bone is removed faster than it is formed, so bone loss occurs and bones become weaker. Therefore, maintaining bone mass and preventing further bone loss are important to keep your skeleton healthy.</p><p>&nbsp;</p><p>Early on, osteoporosis usually has no symptoms. If left untreated, however, it can result in fractures (broken bones). Although fractures usually cause pain, fractures of the bones of the spine may go unnoticed until they cause height loss. Fractures may occur during normal, everyday activity, such as lifting, or from minor injury that would not ordinarily fracture normal bone. &nbsp;Fractures usually occur at the hip, spine, or wrist and can lead not only to pain, but also to considerable deformity and disability (such as stooped posture from curvature of the spine, and loss of mobility).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><u>a-</u></strong><strong><u> </u></strong><strong><u>Do</u></strong><strong><u> </u></strong><strong><u>not take Alendocan if you:</u></strong></p><ul><li>Have certain disorders of the esophagus (the tube that connects your mouth with your stomach)</li><li>Are unable to stand or sit upright for at least 30 minutes.</li><li>Are allergic to any of its ingredients</li><li>Have low blood calcium.</li><li>Have SEVERE kidney disease. If you have any doubts if this applies to you, speak to your physician.</li></ul><p>&nbsp;</p><p><strong>Before you use ALENDOCAN talk to your doctor or pharmacist:</strong></p><ul><li>If you have cancer, gum disease, poor oral hygiene, or diabetes. If you are receiving chemotherapy, radiotherapy, corticosteroids, or immunosuppressive drugs. If you are or have been a smoker, or are a heavy alcohol user. If you have any of these conditions you should consider having a dental examination before starting ALENDOCAN.</li><li>About any medical problems you have or have had, including known kidney disease.</li><li>About any dental problems you have or have had.</li><li>About any allergies.</li><li>If you have any swallowing or digestive problems</li></ul><p>You should always tell your physician about all drugs you are taking or plan to take, including those obtained without a prescription.</p><p>&nbsp;</p><p><strong>Use in children</strong></p><p>ALENDOCAN is not indicated for use in children under 18 years of age.</p><p>&nbsp;</p><p><strong>Use in elderly</strong></p><p>ALENDOCAN works equally well in, and is equally well tolerated by, patients older and younger than 65 years of age.</p><p>&nbsp;</p><p><strong><u>b- Take special care with Alendocan</u></strong></p><p>Your physician has prescribed ALENDOCAN to treat your osteoporosis. ALENDOCAN not only prevents the loss of bone but actually helps to rebuild bone you may have lost and makes bone less likely to fracture. Thus, ALENDOCAN reverses the progression of osteoporosis.</p><p>&nbsp;</p><p>In addition, your physician may recommend one or more of the following lifestyle changes:</p><ul><li><strong>Stop smoking. </strong>Smoking appears to increase the rate at which you lose bone and, therefore, may increase your risk of fracture.</li><li><strong>Exercise. </strong>Like muscles, bones need exercise to stay strong and healthy. Consult your physician before you begin any exercise program.</li><li><strong>Eat a balanced diet. </strong>Your physician can advise you whether to modify your diet or to take any dietary supplements.</li></ul><p>&nbsp;</p><p><u><strong>c-Using other medicines, herbal or dietary supplements</strong></u></p><p>Calcium supplements, antacids, and other oral medications will interfere with the absorption of ALENDOCAN if they are taken at the same time. You must wait at least one-half hour after taking ALENDOCAN before taking any other oral medication.</p><p>&nbsp;</p><p>Calcium and vitamin D are also important for strong bones. Your doctor may ask you to take calcium and vitamin D while you are on ALENDOCAN therapy.</p><p>&nbsp;</p><p><u><strong>d-Using Alendocan with food and drink</strong></u></p><p><strong>&nbsp;</strong></p><p>Do <strong><u>not </u></strong>take ALENDOCAN tablet with:</p><ul><li>mineral water</li><li>coffee or tea</li><li>juice</li></ul><p>&nbsp;</p><p>Although it has not been tested, because of high mineral content, &ldquo;hard water&rdquo; may decrease absorption of ALENDOCAN. If your normal drinking water is classified as &ldquo;hard water&rdquo;, you should consider taking this medication with distilled water (i.e., not mineral water).</p><p>&nbsp;</p><p><u><strong>e. Pregnancy and breast-feeding</strong></u></p><p>Do not take ALENDOCAN if you are pregnant or breast-feeding.</p><p>&nbsp;</p><p><u><strong>f-Driving and using machines:</strong></u></p><p>There have been side effects reported with ALENDOCAN that may affect your ability to drive or operate machinery. Individual responses to ALENDOCAN may vary (See SIDE EFFECTS).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor has prescribed ALENDOCAN tablets once weekly.</p><p>&nbsp;</p><p>These are the important things you must do to help make sure you will benefit from ALENDOCAN.</p><p>&nbsp;</p><ul><li>Choose the day of the week that best fits your schedule. Every week, take one ALENDOCAN tablet on your chosen day.</li><li>After getting up for the day and before taking your first food, beverage, or other medication, take your ALENDOCAN with <strong><u>plain water </u></strong>only as follows: Swallow one tablet with a full glass (200 to 250 mL) of plain water. Do not chew or suck on a tablet of ALENDOCAN.</li><li>After taking your ALENDOCAN tablet do not lie down &ndash; stay fully upright (sitting, standing or walking) for at least 30 minutes and do not lie down until after your first food of the day</li><li>Do not take ALENDOCAN at bedtime or before getting up for the day. This actions will help ALENDOCAN tablet reach your stomach quickly and help reduce the potential for irritation of your esophagus (the tube that connects your mouth with your stomach).</li><li>After taking ALENDOCAN tablet, wait at least 30 minutes before taking your first food, beverage, or other medication of the day, including antacids, calcium supplements and vitamins. ALENDOCAN is effective only if taken when your stomach is empty.</li><li>If you develop difficulty or pain upon swallowing, chest pain, or new or worsening heartburn, stop taking ALENDOCAN immediately and call your doctor.</li><li>If you miss a dose, just take one dose of ALENDOCAN tablet on the morning after you remember. Do not take two doses on the same day. Return to taking one dose once a week, as originally scheduled on your chosen day.</li></ul><p>&nbsp;</p><p><strong><u>a- If you take Alendocan more than you should:</u></strong></p><p>If you take too many tablets, drink a full glass of milk and contact your physician immediately. Do not induce vomiting. Do not lie down.</p><p>&nbsp;</p><p><u><strong>b- If you forget to take Alendocan:</strong></u></p><p>If you miss a dose, just take one ALENDOCAN tablet on the morning after you remember. Do not take two tablets on the same day. Return to taking one tablet once a week, as originally scheduled on your chosen day.</p><p>&nbsp;</p><p><u><strong>c-If you stop using Alendocan:</strong></u></p><p>It is important that you continue taking ALENDOCAN for as long as your doctor prescribes it. ALENDOCAN can treat your osteoporosis only if you continue to take it. It is important to take ALENDOCAN over the long-term to continue to help rebuild bone you may have lost. It is, therefore, important to follow your physician&rsquo;s instructions for taking ALENDOCAN without skipping doses or varying from your prescribed treatment schedule. It is also important to continue to follow your physician&rsquo;s advice on lifestyle changes.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Most patients do not have side effects from ALENDOCAN; however, as with any medicine, ALENDOCAN may have unintended or undesirable effects. Side effects usually have been mild. Some patients may experience digestive disturbances such as nausea, vomiting or black and/or bloody stools. Some digestive disturbances may be severe including irritation or ulceration of the esophagus (the tube that connects your mouth with your stomach), which can cause chest pain, heartburn or difficulty or pain upon swallowing. These reactions may occur especially if patients do not drink the recommended amount of water with ALENDOCAN and/or if they lie down in less than 30 minutes <strong><u>or </u></strong>before their first food of the day. Esophageal reactions may worsen if you continue to take ALENDOCAN after developing symptoms suggesting irritation of the esophagus.</p><p>&nbsp;</p><p>Some patients may experience bone, muscle and/or joint pain which is rarely severe. Patients who develop severe bone, joint, and/or muscle pain should contact their physician. Most patients experienced relief after stopping the drug. Rarely, patients may also experience joint swelling or swelling in their hands or legs. Transient flu-like symptoms (rarely with fever), typically at the start of treatment, have occurred. In rare cases, patients taking ALENDOCAN may get itching or eye pain, or a rash that may be made worse by sunlight. Hair loss has been reported. Rarely, severe skin reactions may occur. Allergic reactions such as hives or, rarely, swelling of the face, lips, tongue and/or throat, which may cause difficulty in breathing or swallowing, may occur. Patients may experience dizziness, vertigo (spinning sensation) or a changed sense of taste. Rarely, symptoms of low blood calcium may occur (for example, numbness or tingling around the mouth or in the hands or feet; muscle spasms in the face, hands, or feet). Rarely stomach or other peptic ulcers (some severe) have occurred. Mouth ulcers have occurred when the tablet was chewed or dissolved in the mouth.</p><p>&nbsp;</p><p>Rarely, patients have had jaw problems associated with delayed healing and infection, often following tooth extraction.</p><p>Rarely, patients have experienced fracture in a specific part of the thigh bone. If you develop new or unusual pain in the hip or thigh, contact your doctor.</p><p>Anytime you have a medical problem you think may be from taking ALENDOCAN, even if it is not listed above, talk to your doctor.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top" colspan="5"><p><strong>SERIOUS</strong><strong> </strong><strong>SIDE</strong><strong> EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM</strong></p></td></tr><tr><td style="vertical-align:top" rowspan="2" colspan="2"><p><strong>Symptoms</strong><strong> / effects</strong></p></td><td style="vertical-align:top" colspan="2"><p><strong>Talk with your doctor or pharmacist</strong></p></td><td style="vertical-align:top" rowspan="2"><p><strong>Stop</strong><strong> </strong><strong>taking</strong><strong> </strong><strong>drug</strong><strong> </strong><strong>and call your doctor or pharmacist</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Only</strong><strong> </strong><strong>if severe</strong></p></td><td style="vertical-align:top"><p><strong>In</strong><strong> </strong><strong>all</strong><strong> cases</strong></p></td></tr><tr><td style="vertical-align:top; width:88px"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top; width:262px"><ul><li>Allergic reactions such as:</li><li>hives</li><li>swelling of the face, lips, tongue and/or throat</li><li>difficulty in breathing or swallowing</li></ul></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>✔</p></td></tr><tr><td style="vertical-align:top; width:88px"><p>&nbsp;</p></td><td style="vertical-align:top; width:262px"><p>Bone, joint, and/or muscle pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:88px"><p>&nbsp;</p></td><td style="vertical-align:top; width:262px"><p>New or unusual pain in the hip or thigh</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:88px"><p>&nbsp;</p></td><td style="vertical-align:top; width:262px"><p>Digestive disturbances causing:</p><ul><li>chest pain</li><li>heartburn</li><li>difficulty or pain upon swallowing</li><li>black and/or bloody stools</li></ul></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>✔</p></td></tr><tr><td style="vertical-align:top; width:88px"><p>&nbsp;</p></td><td style="vertical-align:top; width:262px"><p>Esophageal, stomach or other peptic ulcers</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>✔</p></td></tr><tr><td style="vertical-align:top; width:88px"><p>&nbsp;</p></td><td style="vertical-align:top; width:262px"><p>Jaw problems associated with&nbsp;delayed healing and infection, often following tooth extraction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>✔</p></td></tr><tr><td style="vertical-align:top; width:88px"><p>&nbsp;</p></td><td style="vertical-align:top; width:262px"><p>Eye inflammation associated with eye pain; eye redness; sensitivity to light, decreased vision</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>✔</p></td></tr><tr><td style="vertical-align:top; width:88px"><p>&nbsp;</p></td><td style="vertical-align:top; width:262px"><p>Severe skin reactions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>✔</p></td></tr><tr><td style="vertical-align:top; width:88px"><p>&nbsp;</p></td><td style="vertical-align:top; width:262px"><p>Symptoms of low blood calcium:</p><ul><li>numbness or tingling around the mouth or in the hands or feet</li><li>muscle spasms in the face, hands, or feet</li></ul></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>✔</p></td></tr></tbody></table><p>This is not a complete list of side effects. For any unexpected effects while taking ALENDOCAN, contact your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Keep out of the reach and sight of children.</li><li>Store below 30&deg;C.</li><li>Do not use this medicine after the month and year written after EXP (expiry date) on the container</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>The active substance is Alendronate sodium.</li><li>The other ingredients are magnesium stearate, mannitol and microcrystalline cellulose</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                White, oval, biconvex tablet, engraved “APO” on one side and “ALE70” on one side. It is available in 100 Tablet bottle, and in unit dose packages of 4 and 30.
* Not all packs available or marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Apotex Inc., Toronto, Ontario, M9L 1T9 Canada</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Last revised on 06/2015
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>اليندوكان هو الاسم التجاري للمادة الدوائية صوديوم اليندرونات التي لا تصُرف إلا بموجب وصفة من الطبيب المختص المعالج لك. تنتمي مادة صوديوم اليندرونات إلى فئة من العقاقير غير الهرمونية تسُمى <strong>بيسفوسفونات</strong>.</p><p>يصف لك الطبيب اليندوكان لأنك مصاب بمرض يُسمى تخلخل العظم. ويساعد اليندوكان على إعادة بناء العظام. ويساعد هذا في الوقاية من الإصابة بالكسور.</p><p>وحيث إن مدة استمرار فعالية اليندوكان في علاج تخلخل العظام غير معلومة؛ فينبغي أن تناقش الطبيب بشأن مدى حاجتك إلى الاستمرار في استخدام هذاالدواء بانتظام لتقرير التالي:<br />هل ما يزال اليندوكان مناسباً لك؟</p><p><br />هل تحدث عملية إعادة بناء العظام بشكل طبيعي ومتواصل على مستوى الهيكل العظمي كله؟ أولا؛ً تحدث عملية إزالة (ارتشاف) العظم القديم، ثم عملية تكوُّن العظم الجديد. ويحافظ هذا التوازن بين عمليتي ارتشاف العظام&nbsp;وتكونها على صحة الهيكل العظمي وقوته.</p><p>تخلخل العظام هو ترقق وضعف العظام. وهو حالة شائعة في النساء بعد انقطاع الحيض، وقد يحدث في الرجال أيضًا.</p><p><br />غالباً يحدث تخلخل العظام في النساء بعد انقطاع الحيض بسنوات عديدة، ويحدث انقطاع الحيض عندما تتوقف المبايض عن إنتاج الهرمون الأنثوي - الإستروجين، أو بعد استئصالها (قد يحدث استئصال المبايض عند استئصال الرحم). وكلما حدث الإياس في سن مبكر لدى المرأة؛ زاد احتمال الإصابة بتخلخل العظام. يمكن أن يحدث تخلخل العظام أيضًا في الرجال لعدة أسباب منها الشيخوخة و/أو نقص مستوى هرمون الذكورة - التستوستيرون. في جميع الحالات؛ تحدث إزالة العظام بسرعة أكبر من تكونها؛ ولذا يحدث هشاشة العظام وتزداد العظام ضعفاً. لذا؛ من المهم المحافظة على كتلة العظام والوقاية من تفاقم هشاشة العظام من أجل المحافظة على صحة الهيكل العظمي. في بداية المرض لا يكون لتخلخل العظام أعراض عادة. ولكن إذا ترُكت الحالة بدون علاج؛ فقد تؤدي إلى انكسار العظام. وعلى الرغم من الألم الذي يسببه انكسار العظام؛ فقد تحدث كسور العمود الفقري دون أن يلاحظها المريض حتى تسبب له فقدان الطول. ويمكن أن تحدث كسور العظام أثناء ممارسة الأنشطة اليومية العادية - مثل رفع الأشياء - أو بسبب إصابة صغيرة لا تسبب كسر العظام الطبيعية بشكل عام. وعادة تحدث الكسور في عظام الورك أو العمود الفقري أو المعصم، ويمكن أن تؤدي ليس فقط إلى الشعور بالألم، بل إلى تشوه كبير وإعاقة كبيرة (مثل انحناء القامة وفقدان الحركة).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><u><strong>أ- لا يسُتخدم اليندوكان في الحالات التالية:</strong></u></p><ul><li>وجود اضطرابات في المرئ (الأنبوب الذي يصل الفم بالمعدة)</li><li>عدم القدرة على الوقوف أو الجلوس معتدلا لمدة 30 دقيقة على الأقل.</li><li>الحساسية تجاه أي مكون من مكونات هذا العقار</li><li>نقص الكالسيوم في الدم.</li><li>لإصابة بمرض كلوي خطير. إذا كنت تشك أن أياً من هذه الحالات ينطبق عليك؛ فاستشر الطبيب.</li></ul><p>&nbsp;</p><p><u><strong>قبل استخدام اليندوكان، ينبغي استشارة الطبيب أو الصيدلي في الحالات التالية:</strong></u></p><ul><li>إذا كنت مصاباً بسرطان أو مرض في اللثة أو تدهور في صحة الفم أو داء السكري. إذا كنت تتعاطى علاجًا كيميائياً أو إشعاعياً أو عقاقير الكورتيكوستيرويد أو عقاقير كابتة للمناعة. إذا كنت مدخناً في الوقت الحالي أو سابقاً أو مدمناً للكحول. إذا كانت أي من هذه الحالات تنطبق عليك؛ فينبغي أن تفحص أسنانك طبياً قبل البدء في استخدام اليندوكان.</li><li>عن أي مشكلات طبية تعاني منها حالياً أو كنت تعاني منها سابقاً، بما في ذلك أمراض الكلى المعروفة.</li><li>عن أي مشكلات في الأسنان تعاني منها حالياً أو كنت تعاني منها سابقاً.</li><li>عن أية أنواع حساسية.</li><li>في حالة الإصابة بمشكلات في البلع أو الهضم.</li></ul><p>ينبغي دائمًا أن تخبر الطبيب بكل الأدوية التي تستخدمها أو تنوي استخدامها، بما في ذلك الأدوية التي تحصل عليها بدون وصفة طبية.</p><p><strong>الاستخدام في الأطفال</strong><br />لا يوصى باستخدام اليندوكان في الأطفال تحت 18 سنة.</p><p><br /><strong>الاستخدام في كبار السن</strong><br />تتساوى فعالية اليندوكان ودرجة تحمله في كلٍ من المرضى الذين تزيد أعمارهم عن 65 سنة والذين تقل أعمارهم عن ذلك.</p><p><br /><u><strong>ب- اتخاذ العناية الخاصة مع اليندوكان&nbsp;</strong></u><br />يصف لك الطبيب العقار اليندوكان لعلاجك من مرض تخلخل العظام. يعمل اليندوكان على الوقاية - ليس فقط - من هشاشة العظام، ولكنه يساعد أيضًا في إعادة بناء العظام التي قد يكون فقدها جسمك، ويقلل من احتمال إصابة العظام بالكسور. ومن ثم يعالج اليندوكان تفاقم تخلخل العظام.</p><p>بالإضافة إلى ذلك؛ قد يوصيك الطبيب بواحد أو أكثر من التغيرات التالية في نمط الحياة:</p><ul><li><strong>التوقف عن التدخين</strong>. يبدو أن التدخين يزيد من معدل هشاشة العظام، ومن ثم قد يزيد من احتمال الإصابة بكسور.</li><li><strong>ممارسة الرياضة. </strong>إن العظام - مثلها مثل العضلات - تحتاج إلى التمارين الرياضية لتظل قوية وصحية. ينبغي استشارة الطبيب قبل البدء في أي برنامج رياضي.</li><li><strong>تناول وجبات متوازنة العناصر الغذائية.</strong> يمكن أن ينصحك الطبيب إما بتعديل نظامك الغذائي أو استخدام أي مكملات غذائية.</li></ul><p>&nbsp;</p><p><strong>ج- استخدام أدوية أخرى أو أعشاب طبية أو مكملات غذائية:</strong><br />سوف تتداخل مكملات الكالسيوم ومضادات الحموضة وأدوية فموية أخرى مع امتصاص اليندوكان في حالة تناولها في وقت واحد مع اليندوكان. يجب عليك الانتظار على الأقل نصف ساعة بعد تناول اليندوكان وقبل تناول أي أدوية فموية أخرى.<br />الكالسيوم وفيتامين &quot;د&quot; عنصران مهمان أيضًا لتقوية العظام. يمكن أن يطلب منك الطبيب تناول الكالسيوم وفيتامين &quot;د&quot; أثناء استخدامك العقار اليندوكان.</p><p><br /><u><strong>د- استخدام اليندوكان مع الطعام والشراب</strong></u><br />لا تأخذ قرص اليندوكان مع:</p><ul><li>المياه المعدنية</li><li>القهوة أو الشاي</li><li>العصير</li></ul><p>&nbsp;</p><p>على الرغم من عدم اختبار استخدام &quot;الماء العسر&quot; مع اليندوكان لاحتواء الماء العسر على نسب كبيرة من المعادن؛ فقد يؤدي استخدام الماء العسر إلى تقليل امتصاص اليندوكان. إذا كان الماء الذي تشربه بصفة عادية مصنفاً &quot;ك &quot;ماء عسر&quot;، فينبغي أن تفكر في تناول هذا الدواء مع ماء مقطر (أي ليس معدنياً).</p><p><u><strong>ه- الحمل والرضاعة الطبيعية</strong></u><br />لا يسُتخدم اليندوكان للحوامل والمرضعات.</p><p><br /><u><strong>و- قيادة المركبات واستخدام الآلات:</strong></u><br />وردت تقارير عن حدوث آثار جانبية مع استخدام اليندوكان، وقد تؤثر على قدرتك على قيادة المركبات وتشغيل الآلات. قد تتباين الاستجابات الفردية تجاه اليندوكان (انظر الآثار الجانبية).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يؤخذ قرص اليندوكان مرة واحدة في الأسبوع بوصفة الطبيب المختص.<br />فيما يلي أهم الأمور التي يجب عليك القيام بها لضمان إفادتك من اليندوكان.</p><ol><li>اختر يومًا في الأسبوع يكون هو أنسب وقت لك لتناول هذا الدواء. احرص على تناول قرص واحد من اليندوكان في ذلك اليوم الذي اخترته كل أسبوع.</li><li>بعد الاستيقاظ من النوم وقبل تناول أي طعام أو مشروب أو دواء آخر؛ تناول قرص اليندوكان مع كوب&nbsp;<u><strong>ماء عادي</strong></u> بالطريقة التالية: ابلع قرصًا واحدًا مع كوب كامل (200 إلى 250 مل) من الماء العادي. لا تمضغ قرص اليندوكان ولا تمصه.</li><li>بعد أخذ قرص اليندوكان؛ لا ترقد، وابق منتصب القامة (جالسًا أو واقفاً أو ماشياً) لمدة 30 دقيقة على الأقل، ولا ترقد إلا بعد تناول أول طعام لك في ذلك اليوم.</li><li>لا تتناول اليندوكان عند النوم أو قبل النهوض من السرير. ستساعد هذه الإجراءات على وصول قرص اليندوكان إلى المعدة بسرعة وتقليل احتمال تهيج المرئ (الأنبوب الذي يصل الفم بالمعدة).</li><li>بعد أخذ قرص اليندوكان؛ انتظر 30 دقيقة على الأقل قبل تناول أي طعام أو شراب أو دواء آخر في بداية اليوم، بما في ذلك مضادات الحموضة ومكملات الكالسيوم والفيتامينات. لا تتحقق فعالية اليندوكان إلا على معدة خاوية.</li><li>إذا شعرت بصعوبة أو ألم عند البلع أو ألم في الصدر أو حرقة في المعدة لأول مرة أو تفاقم حرقة المعدة عن القدر المعتاد لديك؛ فتوقف عن تناول اليندوكان على الفور واتصل بالطبيب.</li><li>إذا نسيت جرعة؛ فخذ قرصًا واحدًا من اليندوكان في صباح اليوم الذي تذكرت فيه. ولكن لا تأخذ جرعتين في يوم واحد. وتابع أخذ جرعة واحدة في اليوم المحدد من الأسبوع كما فعلت من البداية.</li></ol><p>&nbsp;</p><p><u><strong>أ- في حالة استخدام جرعة زائدة عن الموصى بها من اليندوكان:</strong></u><br />في حالة تناول عدد مفرط من الأقراص؛ اشرب كوباً كاملا من اللبن واتصل بالطبيب على الفور. لا تحفز نفسك على القيء. لا ترقد.</p><p><br /><u><strong>ب- في حالة نسيان تناول جرعة اليندوكان:</strong></u><br />إذا نسيت جرعة؛ فخذ قرصًا واحدًا من اليندوكان في صباح اليوم الذي تذكرت فيه. ولكن لا تأخذ قرصين في يوم واحد. وتابع أخذ قرص واحد في اليوم المحدد من الأسبوع كما فعلت من البداية.</p><p>&nbsp;</p><p><u><strong>ج- في حالة التوقف عن استخدام اليندوكان:</strong></u><br />من المهم جدًا الاستمرار في تناول اليندوكان ما دام الطبيب يصفه لك. يمكن أن يعالج اليندوكان تخلخل العظام عندك فقط في حالة الاستمرار في تناوله. من المهم تناول اليندوكان على المدى الطويل للاستمرار في إعادة بناء العظام التي قد تكون فقدتها. لهذا من المهم اتباع تعليمات الطبيب المعالج لك بشأن تناول اليندوكان مع تجنب ترك جرعات ومخالفة مواعيد تناول الجرعة التي وصفها لك الطبيب. من المهم أيضًا الاستمرار في اتباع نصائح الطبيب بشأن تغييرات نمط الحياة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>لا يصُاب معظم المرضى بآثار جانبية من اليندوكان؛ ولكن - مثل أي دواء - يمكن أن يسبب اليندوكان آثارًا غير مقصودة أو مزعجة. كانت الآثار الجانبية المبلغ عنها بسيطة عادة. يمكن أن يصُاب بعض المرضى باضطرابات هضمية مثل الغثيان أو القيء أو براز أسود و/ أو مدمم. يمكن أن تحدث بعض الاضطرابات الهضمية الشديدة بما فيها تهيج أو تقرح المرئ (الأنبوب الذي يصل الفم بالمعدة)،ويمكن أن تسبب ألمًا في الصدر أو حرقة المعدة أو صعوبة في البلع أو شعور بالألم فيه. يمكن أن تحدث هذه الآثار الجانبية خصوصًا إذا كان المريض لا يشرب الكمية الموصى بها من الماء مع قرص اليندوكان و/أو إذا كان يرقد قبل مرور 30 دقيقة من وقت تناول القرص أو قبل تناول أول طعام له في اليوم. يمكن أن تتفاقم الآثار الجانبية في المرئ في حالة الاستمرار في تناول اليندوكان بعد ظهور أعراض ترجح تهيج المرئ.</p><p><br />يمكن أن يصُاب بعض المرضى بألم في العظام أو العضلات و/أو المفاصل، ونادرًا ما يكون شديدًا. يجب على المرضى الذين يصُابون بألم شديد في العظام أو المفاصل و/أو العضلات - يجب عليهم الاتصال بالطبيب. يزول هذا الألم لدى معظم المرضى بعد التوقف عن تناول هذا العقار. نادرًا؛ يمكن أن يصُاب المرضى بتورم المفاصل أو تورم اليدين أو الرجلين. حدثت أعراض عابرة مشابهة للأنفلونزا (مصحوبة بحمى نادرًا)، وتكون في بداية العلاج عادة. في حالات نادرة يمكن أن يصُاب المرضى الذين يستخدمون اليندوكان بحكة أو ألم في العينين أو طفح جلدي قد يزداد سوءًا مع التعرض لضوء الشمس. وردت تقارير عن حدوث سقوط الشعر. في حالات نادرة؛ يمكن أن تحدث ردود فعل جلدية شديدة. ردود فعل تحسسية مثل الشرى، وتورم الوجه والشفتين واللسان و/أو الحلق - قد تؤدي إلى الشعور بصعوبة أثناء التنفس أو البلع. قد يصُاب المرضى بالدوار والدوخة أو تغير المذاق. نادرًا قد تحدث أعراض نقص كالسيوم الدم (مثل خدر أو نمل حول الفم أو اليدين أو القدمين، تقلصات عضلية في الوجه واليدين أو القدمين) في حالات نادرة؛ حدثت قرحات معدية أو أثنى عشرية (بعضها شديد). حدثت قرحات فموية عند مضغ القرص أو إذابته في الفم.</p><p>&nbsp;</p><p>في حالات نادرة؛ أصُيب المرضى بمشكلات في الفك مصحوبة بتأخر في الشفاء والعدوى، وكانت تحدث عادة بعد خلع أسنان.<br />في حالات نادرة؛ أصُيب مرضى بكسور في جزء معين من عظم الفخذ. إذا أصٌبت بألم جديد أو غير معتاد في الفخذ أو الورك، فاتصل بالطبيب.<br />إذا واجهت مشكلة طبية تظن أنها بسبب تناول اليندوكان/؛ حتى لو لم تكن ضمن ما سبق؛ فاستشر الطبيب.</p><p>&nbsp;</p><table border="1" align="right" cellspacing="1" cellpadding="1" style="width:822px"><tbody><tr><td colspan="4" style="text-align:center; width:819px"><p><strong>الآثار الجانبية الخطيرة، ومدى تكرارها وكيفية التعامل معها</strong></p></td></tr><tr><td rowspan="2" style="width:389px"><p><strong>العرض/الأثر</strong></p></td><td rowspan="1" colspan="2" style="width:179px"><p><strong>تحدث إلى الطبيب أو الصيدلي </strong></p></td><td rowspan="2" style="width:259px"><p><strong>توقف عن تناول الدواء واتصل بالطبيب أو الصيدلي</strong></p></td></tr><tr><td style="width:100px"><p><strong>في الحالات&nbsp;الخطرة فقط</strong></p></td><td style="width:80px"><p><strong>في كل الحالات</strong></p></td></tr><tr><td style="width:389px"><p>تفاعلات تحسسية مثل:</p><ul><li>الشرى</li><li>تورم الوجه أو الشفتين أو اللسان و/أو الحلق</li><li>صعوبة في التنفس أو البلع</li></ul></td><td style="width:100px"><p>&nbsp;</p><ul></ul></td><td style="width:80px">&nbsp;</td><td style="width:259px"><p>✔</p></td></tr><tr><td style="width:389px"><p>ألم في العظام أو المفاصل و/أو ألم في العضلات</p></td><td style="width:100px"><p>&nbsp;</p></td><td style="width:80px">✔</td><td style="width:259px"><p>&nbsp;</p></td></tr><tr><td style="width:389px"><p>ألم جديد أو غير معتاد في الورك أو الفخذ</p></td><td style="width:100px"><p>&nbsp;</p></td><td style="width:80px">✔</td><td style="width:259px"><p>&nbsp;</p></td></tr><tr><td style="width:389px"><p>اضطرابات هضمية تسبب:</p><ul><li>ألم في الصدر</li><li>حرقة القلب</li><li>صعوبة أو ألم في البلع</li><li>براز أسود و/أو مدمم</li></ul></td><td style="width:100px"><p>&nbsp;</p></td><td style="width:80px">&nbsp;</td><td style="width:259px"><p>✔</p></td></tr><tr><td style="width:389px"><p>قرحة في المرئ أو المعدة أو قرحة معدية</p></td><td style="width:100px"><p>&nbsp;</p></td><td style="width:80px">&nbsp;</td><td style="width:259px"><p>✔</p></td></tr><tr><td style="width:389px"><p>مشكلات في الفك مصحوبة بتأخر في الشفاء<br />وعدوى، وكانت تحدث عادة بعد خلع أسنان.</p></td><td style="width:100px"><p>&nbsp;</p></td><td style="width:80px">&nbsp;</td><td style="width:259px"><p>✔</p></td></tr><tr><td style="width:389px"><p>التهاب في العينين مصحوب بألم&nbsp;في العين المصابة، احمرار العينين;</p><ul><li>الحساسية للضوء</li><li>ضعف</li><li>الرؤية</li></ul></td><td style="width:100px"><p>&nbsp;</p></td><td style="width:80px">&nbsp;</td><td style="width:259px"><p>✔</p></td></tr><tr><td style="width:389px"><p>تفاعلات جلدية شديدة</p></td><td style="width:179px"><p>&nbsp;</p></td><td style="width:179px">&nbsp;</td><td style="width:259px"><p>✔</p></td></tr><tr><td style="width:389px"><p>أعراض نقص كالسيوم الدم:</p><ul><li>خدر أو نمل أو وخز حول الفم أو في اليدين أو القدمين</li><li>تقلصات عضلية في الوجه أو اليدين أو القدمين</li></ul></td><td style="width:179px"><p>&nbsp;</p></td><td style="width:179px">&nbsp;</td><td style="width:259px"><p>✔</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>وهذه ليست كل الآثار الجانبية. في حالة حدوث أي آثار غير متوقعة أثناء استخدام اليندوكان، يجب الاتصال بالطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>يجب حفظ الدواء بعيدًا عن متناول الأطفال ونظرهم.</li><li>يخزن في درجة حرارة أقل من ۳۰ درجة مئوية.</li><li>تاريخ الصلاحية) على العلبة. ) EXP - لا تستخدم هذا الدواء بعد شهر من التاريخ المكتوب بعد الرمز</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; المادة الفعالة هي صوديوم اليندرونات.<br />&bull; المكونات الأخرى هي ستيريت ماغنيسوم، مانيتول وسيلولوز دقيق البلورات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>، قرص أبيض بيضاوي محدب من الجانبين، منقوش على أحد جانبي كل قرص الرمز&nbsp;&nbsp;&ldquo;APO&rdquo;&nbsp;وعلى الجانب الآخر الرمز&nbsp;&nbsp;(ALE 70).</p><p>يتوفر هذا الدواء في عبوة زجاجية بها ۱۰۰ قرص، وفي عبوات محددة الجرعة بها ٤ إلى ۳۰ جرعة.<br />* قد لا يتم تسويق العبوات بكل الأحجام.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>أبوتكس إنك، تورنتو، أونتاريو، ام ۹ ال ۱تي ۹ كندا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة بتاريخ 06/2015
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ALENDOCAN Alendronate Sodium Tablets, 5 mg, 10 mg, 40 mg, 70 mg Alendronate.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet of ALENDOCAN contains 6.53, 13.05, 52.20 or 91.35 mg of alendronate monosodium salt trihydrate, which is the molar equivalent to 5, 10 and 40 mg and 70 mg, respectively, of alendronate and the following non-medicinal ingredients: magnesium stearate, mannitol and microcrystalline cellulose.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ALENDOCAN 5 mg: each white, round, flat-faced, bevelled edged tablet, engraved “A” on one side and “5” on the other, contains alendronate sodium equivalent to 5 mg alendronate.
Available in bottles of 100 and 500, and in unit dose packages of 30.
ALENDOCAN 10 mg: each white, round, biconvex tablet, engraved “APO” on one side and “10” on the other, contains alendronate sodium equivalent to 10 mg alendronate.  Available in bottles of 100 and 500, and in unit dose packages of 30.
ALENDOCAN 40 mg: each white, triangular, biconvex tablet, engraved “APO” over “40” on one side and plain on the other, contains alendronate sodium equivalent to 40 mg alendronate. Available in bottles of 100, and in unit dose packages of 30.
ALENDOCAN 70 mg: each white, oval, biconvex tablet, engraved “APO” on one side and “ALE70” on one side, contains alendronate sodium equivalent to 70 mg alendronate.  Available in bottles of 100, and in unit dose packages of 4 and 30.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ALENDOCAN (alendronate sodium) is indicated for:</p><ul><li>The treatment and prevention of osteoporosis in postmenopausal women.<ul><li>For the treatment of osteoporosis, ALENDOCAN increases bone mass and prevent fractures, including those of the hip and spine (vertebral compression fractures). Osteoporosis may be confirmed by the finding of low bone mass (for example, at least 2.0 standard deviations below the premenopausal mean) or by the presence or history of osteoporotic fracture.</li><li>For the prevention of osteoporosis, ALENDOCAN may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture. Bone loss is particularly rapid in postmenopausal women younger than age 60. Risk factors often associated with the development of postmenopausal osteoporosis include early menopause; moderately low bone mass; thin body build; Caucasian or Asian race; and family history of osteoporosis. The presence of such risk factors may be important when considering the use of ALENDOCAN for prevention of osteoporosis.</li></ul></li><li>The treatment of osteoporosis in men to reduce the incidence of fractures.</li><li>The treatment and prevention of glucocorticoid-induced osteoporosis in men and women.</li><li>The treatment of Paget&rsquo;s disease of bone in men and women.<ul><li>Treatment is indicated in patients with Paget&rsquo;s disease of bone having serum alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for future complications from their disease.</li></ul></li></ul><p><strong>Important limitations of use: </strong>The optimal duration of use has not been determined. Patients should have the need for continued therapy re-evaluated on a periodic basis (see DOSAGE AND ADMINISTRATION).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Recommended Dose</u></strong></p><p><strong>Treatment of Osteoporosis in Postmenopausal Women and in Men</strong></p><p>The recommended dosage is:</p><ul><li>one 70 mg tablet once weekly or</li><li>one 10 mg tablet once daily.</li></ul><p>&nbsp;</p><p><strong>Prevention of Osteoporosis in Postmenopausal Women</strong></p><p>The recommended dosage is 5 mg once a day.</p><p>&nbsp;</p><p><strong>Treatment and Prevention of Glucocorticoid-Induced Osteoporosis in Men and Women </strong></p><p>The recommended dosage is 5 mg once a day, except for postmenopausal women not receiving estrogen, for whom the recommended dosage is 10 mg once a day.</p><p>&nbsp;</p><p><strong>Paget&rsquo;s Disease of Bone in Men and Women</strong></p><p>The recommended treatment regimen is 40 mg once a day for six months.</p><p>&nbsp;</p><p><strong>Retreatment of Paget&rsquo;s Disease</strong></p><p>In clinical studies in which patients were followed every six months, relapses during the 12 months following therapy occurred in 9% (3 out of 32) of patients who responded to treatment with alendronate. &nbsp;Specific retreatment data are not available, although responses to alendronate were similar in patients who had received prior bisphosphonate therapy and those who had not. Retreatment with ALENDOCAN may be considered, following a six-month post-treatment evaluation period, in patients who have relapsed based on increases in serum alkaline phosphatase (which should be measured periodically). &nbsp;Retreatment may also be considered in those who failed to normalize their serum alkaline phosphatase.</p><p>The optimal duration of bisphosphonate treatment for osteoporosis has not been established. The need for continued treatment should be re-evaluated periodically based on the benefits and potential risks of ALENDOCAN on an individual patient basis.</p><p>&nbsp;</p><p><strong><u>Dosage Adjustment</u></strong></p><p>No dosage adjustment is necessary for the elderly or for patients with mild-to-moderate renal insufficiency (creatinine clearance 0.58 to 1 mL/s [35 to 60 mL/min]). &nbsp;ALENDOCAN is not recommended for patients with more severe renal insufficiency (creatinine clearance &lt;0.58 mL/s [&lt; 35 mL/min]) due to lack of experience.</p><p>&nbsp;</p><p><strong><u>Missed Dose</u></strong></p><p>Patients should be instructed that if they miss a dose of ALENDOCAN 70 mg once weekly, they should take one dose on the morning after they remember. &nbsp;They should not take two doses on the same day but should return to taking one dose once a week, as originally scheduled on their chosen day.</p><p>&nbsp;</p><p><strong>Administration</strong></p><p>ALENDOCAN must be taken at least one-half hour before the first food, beverage, or medication of the day with plain water only. Other beverages (including mineral water), food, and some medications are known to reduce the absorption of ALENDOCAN (see INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION). Waiting less than 30 minutes will lessen the effect of ALENDOCAN by decreasing its absorption into the body.</p><p>&nbsp;</p><p>ALENDOCAN should only be taken upon arising for the day. To facilitate delivery to the stomach and thus reduce the potential for esophageal irritation, an ALENDOCAN tablet should be swallowed with a full glass of water (200-250 mL). Patients should not lie down for at least 30 minutes and until after their first food of the day. ALENDOCAN should not be taken at bedtime or before arising for the day. Failure to follow these instructions may increase the risk of esophageal adverse experiences (see WARNINGS AND PRECAUTIONS).</p><p>&nbsp;</p><p>All patients must receive supplemental calcium and Vitamin D, if dietary intake is inadequate.</p><p>&nbsp;</p><p>Although no specific studies have been conducted on the effects of switching patients on another therapy for osteoporosis or Paget&#39;s disease to ALENDOCAN, there are no known or theoretical safety concerns related to ALENDOCAN in patients who previously received any other antiosteoporotic or antipagetic therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Patients who are hypersensitive to this drug or to any ingredient in the formulation.  For a complete listing, see the section 6.1 List of Excipients of the product monograph.

• Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia

•	Inability to stand or sit upright for at least 30 minutes.
•	Hypocalcemia (see WARNINGS AND PRECAUTIONS).
•	Renal insufficiency with creatinine clearance < 0.58 mL/s [< 35 mL/min] (see DOSAGE AND ADMINISTRATION).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>General</u></strong></p><p>To facilitate delivery to the stomach and thus reduce the potential for esophageal irritation, patients should be instructed to swallow each tablet of ALENDOCAN (alendronate sodium) with a <u>full</u>&nbsp;glass of water. Patients should be instructed not to lie down for at least 30 minutes <u>and</u> &nbsp;&nbsp;until after their first food of the day. &nbsp;Patients should not chew or suck on the tablet because of a potential for oropharyngeal ulceration. &nbsp;Patients should be specifically instructed not to take ALENDOCAN at bedtime or before arising for the day. &nbsp;Patients should be informed that failure to follow these instructions may increase their risk of esophageal problems. Patients should be instructed that if they develop symptoms of esophageal disease (such as difficulty or pain upon swallowing, retrosternal pain or new or worsening heartburn) they should stop taking ALENDOCAN immediately and consult their physician.</p><p>Causes of osteoporosis other than estrogen deficiency, aging and glucocorticoid use should be considered.</p><p>&nbsp;</p><p><u><strong>Osteonecrosis of the jaw</strong></u></p><p>Osteonecrosis of the jaw (ONJ) has been reported in patients with cancer receiving treatment regimens including bisphosphonates. The majority of reports occurred following tooth extractions with delayed healing and involved cancer patients treated with intravenous bisphosphonates. &nbsp;Many of these patients were also receiving chemotherapy and corticosteroids. However, some cases have also occurred in patients receiving oral bisphosphonate treatment for postmenopausal osteoporosis and other diagnoses. The majority of reported cases have been associated with dental procedures such as tooth extraction. &nbsp;Many had signs of local infection, including osteomyelitis.</p><p>&nbsp;</p><p>A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with concomitant risk factors. Known risk factors for osteonecrosis of the jaw include a diagnosis of cancer, concomitant therapies (e.g. chemotherapy, radiotherapy, corticosteroids, immunosuppressive drugs), poor oral hygiene, co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, diabetes mellitus), smoking, and heavy alcohol use.</p><p>&nbsp;</p><p>Patients who develop osteonecrosis of the jaw should receive appropriate antibiotic therapy &nbsp;and/or oral surgery and discontinuation of bisphosphonate therapy should be considered based on individual benefit/risk assessment. Dental surgery may exacerbate the condition. &nbsp;For patients requiring dental procedures (e.g. tooth extraction, dental implants), there are no definitive data available to establish whether discontinuation of bisphosphonate treatment reduces the risk of ONJ.</p><p>&nbsp;</p><p>Clinical judgment of the treating physician and/or oral surgeon should guide the management plan, including bisphosphonate treatment, of each patient based on individual benefit/risk assessment.</p><p>&nbsp;</p><p><strong>Musculoskeletal</strong></p><p>In post marketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain has been reported in patients taking bisphosphonates that are approved for the prevention and treatment of osteoporosis (see UNDESIRABLE EFFECTS). However, such reports have been infrequent. This category of drugs includes alendronate. Most of the patients were postmenopausal women. The time to onset of symptoms varied from one day to several months after starting the drug. Most patients had relief of symptoms after stopping the medication. A subset had recurrence of symptoms when re-challenged with the same drug or another bisphosphonate.</p><p>&nbsp;</p><p>In placebo-controlled clinical studies of alendronate, the percentages of patients with these symptoms were similar in the alendronate and placebo groups.</p><p>&nbsp;</p><p>Low-energy fractures of the subtrochanteric and proximal femoral shaft have been reported in some long-term (time to onset in the majority of reports ranged from 18 months to 10 years) alendronate-treated patients. Some were stress fractures (some of which were reported as insufficiency fractures) occurring in the absence of apparent trauma. Some patients experienced prodromal pain in the affected area, often associated with imaging features of stress fracture, weeks to months before a complete fracture occurred. Approximately one third of these fractures were bilateral; therefore the contralateral femur should be examined in patients who have sustained a femoral shaft stress fracture. Poor healing of these fractures was also reported.</p><p>&nbsp;</p><p>Patients with suspected stress fractures should be evaluated, including evaluation for causes and risk factors of stress fractures (e.g., vitamin D deficiency, malabsorption, glucocorticoid use, lower extremity arthritis or fracture, previous stress fracture, extreme or increased exercise, diabetes mellitus, chronic alcohol abuse), and receive appropriate orthopedic care. Interruption of alendronate therapy in patients with stress fractures should be considered based on individual benefit/risk assessment.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Endocrine and Metabolism</u></strong></p><p>Hypocalcemia must be corrected before initiating therapy with ALENDOCAN (see CONTRAINDICATIONS). Other disorders affecting mineral metabolism (such as Vitamin D deficiency) should be treated. &nbsp;In patients with these conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with ALENDOCAN. Symptomatic hypocalcemia has been reported rarely, both in patients with predisposing conditions and patients without known predisposing conditions. &nbsp;Patients should be advised to report to their physicians any symptoms of hypocalcemia, such as paresthesias or muscle spasms. &nbsp;Physicians should carefully evaluate patients who develop hypocalcemia during therapy with ALENDOCAN for predisposing conditions.</p><p>&nbsp;</p><p>Due to the positive effects of ALENDOCAN to increase bone mineral, small, asymptomatic decreases in serum calcium and phosphate may occur, especially in patients with Paget&rsquo;s disease, in whom the pretreatment rate of bone turnover may be greatly elevated, and in patients receiving glucocorticoids, in whom calcium absorption may be decreased.</p><p>&nbsp;</p><p>Ensuring adequate calcium and Vitamin D intake is especially important in patients with Paget&rsquo;s disease of bone and in patients receiving glucocorticoids.</p><p>&nbsp;</p><p><strong><u>G</u><u>a</u><u>s</u><u>t</u><u>r</u><u>o</u><u>i</u><u>n</u><u>t</u><u>e</u><u>s</u><u>t</u><u>i</u><u>n</u><u>a</u><u>l</u></strong></p><p>ALENDOCAN, like other bisphosphonates, may cause local irritation of the upper gastrointestinal mucosa.</p><p>&nbsp;</p><p>Esophageal adverse experiences, such as esophagitis, esophageal ulcers and esophageal erosions, rarely followed by esophageal stricture or perforation, have been reported in patients receiving treatment with ALENDOCAN. In some cases these have been severe and required hospitalization. Physicians should therefore be alert to any signs or symptoms signaling a possible esophageal reaction and patients should be instructed to discontinue ALENDOCAN immediately and seek medical attention if they develop dysphagia, odynophagia, retrosternal pain or new or worsening heartburn.</p><p>&nbsp;</p><p>The risk of severe esophageal adverse experiences appears to be greater in patients who lie down after taking ALENDOCAN and/or who fail to swallow it with the recommended amount of water, and/or who continue to take ALENDOCAN after developing symptoms suggestive of esophageal irritation. Therefore, it is very important that the full dosing instructions are provided to, and understood by, the patient (see DOSAGE AND ADMINISTRATION).</p><p>&nbsp;</p><p>Because of possible irritant effects of ALENDOCAN on the upper gastrointestinal mucosa and a potential for worsening of the underlying disease, caution should be used when</p><p>ALENDOCAN is given to patients with active upper gastrointestinal problems, such as dysphagia, esophageal diseases (including known Barrett&#39;s esophagus), gastritis, duodenitis, or ulcers.</p><p>&nbsp;</p><p>While no increased risk was observed in extensive clinical trials, there have been rare (post- marketing) reports of gastric and duodenal ulcers, some severe and with complications.</p><p>&nbsp;</p><p><strong>Ophthalmologic</strong></p><p>Ocular disturbances including conjunctivitis, uveitis, episcleritis and scleritis have been reported with alendronate therapy. Patients with ocular events other than uncomplicated conjunctivitis should be referred to an ophthalmologist for evaluation. If ocular inflammatory symptoms are observed, treatment may need to be discontinued.</p><p>&nbsp;</p><p><u><strong>Special Populations</strong></u></p><p><strong>&nbsp;</strong></p><p><strong>Pregnant</strong><strong> </strong><strong>Women:</strong></p><p>Alendronate has not been studied in pregnant women and should not be given to them.</p><p>&nbsp;</p><p><strong>Nursing Women:</strong></p><p>Alendronate has not been studied in nursing mothers and should not be given to them.</p><p>&nbsp;</p><p><strong>Pediatrics (&lt; 18 years of age):</strong></p><p>ALENDOCAN is not indicated for use in children.</p><p>&nbsp;</p><p><strong>Geriatrics:</strong></p><p>In clinical studies, there was no age-related difference in the efficacy or safety profiles of alendronate.</p><p>&nbsp;</p><p><strong>Monitoring and Laboratory Tests:</strong></p><p>Not Applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Overview</u></strong></p><p>Animal studies have demonstrated that alendronate is highly concentrated in bone and is retained only minimally in soft tissue. &nbsp;No metabolites have been detected. &nbsp;Although alendronate is &nbsp;bound approximately 78% to plasma protein in humans, its plasma concentration is so low after oral dosing that only a small fraction of plasma-binding sites is occupied, resulting in a minimal potential for interference with the binding of other drugs. &nbsp;Alendronate is not excreted through &nbsp;the acidic or basic transport systems of the kidney in rats, and thus it is not anticipated to &nbsp;interfere with the excretion of other drugs by those systems in humans. &nbsp;In summary, ALENDOCAN is not expected to interact with other drugs based on effects on protein binding, renal excretion, or metabolism of other drugs.</p><p>&nbsp;</p><p><strong><u>Drug-Drug Interactions</u></strong></p><p>If taken at the same time it is likely that calcium supplements, antacids, other multivalent cations and other oral medications will interfere with absorption of ALENDOCAN. &nbsp;Therefore, patients must wait at least one-half hour after taking ALENDOCAN before taking any other oral medication.</p><p>Intravenous ranitidine was shown to double the bioavailability of oral alendronate. The clinical significance of this increased bioavailability and whether similar increases will occur in patients given oral H2-antagonists is unknown; no other specific drug interaction studies were performed.</p><p>&nbsp;</p><p>Concomitant use of hormone replacement therapy (HRT [estrogen &plusmn; progestin]) and alendronate was assessed in two clinical studies of one or two years&rsquo; duration in postmenopausal osteoporotic women. &nbsp;Combined use of alendronate and HRT resulted in greater increases in bone mass, together with greater decreases in bone turnover, than seen with either treatment alone. &nbsp;In these studies, the safety and tolerability profile of the combination was consistent with those of the individual treatments (see UNDESIRABLE EFFECTS, Clinical Studies, Concomitant Use with Estrogen/Hormone Replacement Therapy). &nbsp;The studies were too small to detect antifracture efficacy, and no significant differences in fracture incidence among the treatment groups were found.</p><p>Specific interaction studies were not performed. &nbsp;Alendronate was used in osteoporosis studies in men, postmenopausal women, and glucocorticoid users, with a wide range of commonly prescribed drugs without evidence of clinical adverse interactions.</p><p>In clinical studies, the incidence of upper gastrointestinal adverse events was increased in patients receiving daily therapy with dosages of alendronate greater than 10 mg and acetylsalicylic acid-containing products. This was not observed in a study with alendronate 70 mg once weekly.</p><p>Alendronate may be administered to patients taking nonsteroidal anti-inflammatory drugs (NSAIDs). &nbsp;In a 3-year, controlled, clinical study (n=2027) during which a majority of patients received concomitant NSAIDs, the incidence of upper gastrointestinal adverse events was similar in patients taking alendronate 5 or 10 mg/day compared to those taking placebo. &nbsp;However, since NSAID use is associated with gastrointestinal irritation, caution should be used during concomitant use with ALENDOCAN.</p><p>&nbsp;</p><p><strong>Drug-Food Interactions</strong></p><p>Food and beverages other than <u>plain water </u>may markedly reduce the absorption and &nbsp;effectiveness of alendronate. ALENDOCAN must be taken at least one-half hour before the first food, beverage, or medication of the day with plain water only (see DOSAGE AND ADMINISTRATION, Administration).</p><p>&nbsp;</p><p><strong>Drug-Herb Interactions</strong></p><p>Herbal products may interfere with the absorption of alendronate. ALENDOCAN must be taken at least one-half hour before any herbal products.</p><p>&nbsp;</p><p><strong>Drug-Laboratory Interactions</strong></p><p>Interactions with laboratory tests have not been established.</p><p>&nbsp;</p><p><strong>Drug-Lifestyle Interactions</strong></p><p>No studies on the effects on the ability to drive and use machines have been performed. However, certain adverse reactions that have been reported with alendronate (e.g., dizziness, vertigo, visual disturbances, and severe bone, muscle or joint pain) may affect some patients&rsquo; ability to drive or operate machinery. Individual responses to alendronate may vary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Effects</strong><strong> </strong><strong>on Fertility</strong></p><p>Alendronate had no effect on fertility or reproductive performance (male or female) in rats at &nbsp;oral doses up to 5 mg/kg/day. &nbsp;The only drug-related effect seen in these studies was difficulty in parturition in rats, which is directly related to pharmacologically mediated hypocalcemia. &nbsp;This effect can be prevented in rats by calcium supplementation. &nbsp;Furthermore, a clear no-effect level of 1.25 mg/kg/day was established.</p><p>&nbsp;</p><p><strong>Use in Pregnancy (Category C)</strong></p><p>Animal studies in rats have revealed evidence of incomplete fetal ossification, protracted parturition, and maternal toxicity at alendronate doses 1 to 9 times the 10 mg human dose (based on mg/m2). No similar effects were noted in rabbits treated at doses 50 times the human 10 mg dose (based on mg/m2). There are no controlled data in human pregnancy. Alendronate is only recommended for use during pregnancy when there are no alternatives and benefit outweighs risk.</p><p>&nbsp;</p><p><strong>Use in Lactation</strong></p><p>Though absorption of alendronate by a breastfed infant is unlikely, an alternate drug may be preferred since no information exists on its use during breastfeeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.</p><p>&nbsp;</p><p>However, certain adverse reactions that have been reported with alendronate (e.g., dizziness, vertigo, visual disturbances, and severe bone, muscle or joint pain) may affect some patients&rsquo; ability to drive or operate machinery. Individual responses to alendronate may vary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Clinical</u></strong><strong><u> Trial Adverse Drug Reactions</u></strong></p><p><em>Because</em><em> </em><em>clinical</em><em> trials are conducted under very specific conditions the adverse drug reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.</em></p><p><em>&nbsp;</em></p><p>In clinical studies, alendronate was generally well tolerated. &nbsp;In studies of up to five years in duration, side effects, which usually were mild, generally did not require discontinuation of therapy.</p><p>Alendronate has been evaluated for safety in clinical studies in approximately 7200 postmenopausal women.</p><p>&nbsp;</p><p><u><strong>Treatment of Osteoporosis</strong></u></p><p><strong>Postmenopausal</strong><strong> </strong><strong>Women</strong></p><p>In two, three-year, placebo-controlled, double-blind, multicenter studies (United States and Multinational) of virtually identical design, with a total of 994 postmenopausal women, the overall safety profiles of alendronate 10 mg/day and placebo were similar. &nbsp;Discontinuation of therapy due to any clinical adverse experience occurred in 4.1% of 196 patients treated with alendronate 10 mg/day and 6.0% of 397 patients treated with placebo.</p><p>Adverse experiences considered by the investigators as possibly, probably, or definitely drug- related in &ge; 1% of patients treated with either alendronate 10 mg/day or placebo are presented in the following table.<!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s1026" style='width:471.5pt;
 height:.5pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="9430,10">
 <v:group id="_x0000_s1027" style='position:absolute;left:5;top:5;width:9421;
  height:2' coordorigin="5,5" coordsize="9421,2">
  <v:shape id="_x0000_s1028" style='position:absolute;left:5;top:5;width:9421;
   height:2' coordorigin="5,5" coordsize="9421,0" path="m5,5r9420,e" filled="f"
   strokeweight=".16053mm">
   <v:path arrowok="t"/>
  </v:shape></v:group><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="630" height="2" src="file:///C:/Users/ahmed/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:471.5pt;
 height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>Drug-Related* Adverse Experiences Reported in <u>&gt; </u>1% of Patients Treated for Osteoporosis</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:331px" rowspan="2"><p>&nbsp;</p></td><td style="vertical-align:top; width:111px" rowspan="2" colspan="1"><p><strong>Alendronate</strong></p><p><strong>10 mg/day</strong></p><p><strong>%</strong></p><p><strong>(n</strong><strong> </strong><strong>= 196)</strong></p></td></tr><tr><td style="height:200px; vertical-align:top"><p><strong>Placebo</strong></p><p><strong>%</strong></p><p><strong>(n</strong><strong> </strong><strong>= 397)</strong></p></td></tr><tr><td style="vertical-align:top; width:331px"><p><strong>Gastrointestinal</strong></p></td><td style="vertical-align:top; width:111px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:331px"><p>Abdominal pain</p></td><td style="vertical-align:top; width:111px"><p>6.6</p></td><td style="vertical-align:top"><p>4.8</p></td></tr><tr><td style="vertical-align:top; width:331px"><p>Nausea</p></td><td style="vertical-align:top; width:111px"><p>3.6</p></td><td style="vertical-align:top"><p>4.0</p></td></tr><tr><td style="vertical-align:top; width:331px"><p>Dyspepsia</p></td><td style="vertical-align:top; width:111px"><p>3.6</p></td><td style="vertical-align:top"><p>3.5</p></td></tr><tr><td style="vertical-align:top; width:331px"><p>Constipation</p></td><td style="vertical-align:top; width:111px"><p>3.1</p></td><td style="vertical-align:top"><p>1.8</p></td></tr><tr><td style="vertical-align:top; width:331px"><p>Diarrhea</p></td><td style="vertical-align:top; width:111px"><p>3.1</p></td><td style="vertical-align:top"><p>1.8</p></td></tr><tr><td style="vertical-align:top; width:331px"><p>Flatulence</p></td><td style="vertical-align:top; width:111px"><p>2.6</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td style="vertical-align:top; width:331px"><p>Acid regurgitation</p></td><td style="vertical-align:top; width:111px"><p>2.0</p></td><td style="vertical-align:top"><p>4.3</p></td></tr><tr><td style="vertical-align:top; width:331px"><p>Esophageal ulcer</p></td><td style="vertical-align:top; width:111px"><p>1.5</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td style="vertical-align:top; width:331px"><p>Vomiting</p></td><td style="vertical-align:top; width:111px"><p>1.0</p></td><td style="vertical-align:top"><p>1.5</p></td></tr><tr><td style="vertical-align:top; width:331px"><p>Dysphagia</p></td><td style="vertical-align:top; width:111px"><p>1.0</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td style="vertical-align:top; width:331px"><p>Abdominal distention</p></td><td style="vertical-align:top; width:111px"><p>1.0</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td style="vertical-align:top; width:331px"><p>Gastritis</p></td><td style="vertical-align:top; width:111px"><p>0.5</p></td><td style="vertical-align:top"><p>1.3</p></td></tr><tr><td style="vertical-align:top; width:331px"><p><strong>Musculoskeletal</strong></p></td><td style="vertical-align:top; width:111px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:331px"><p>Musculoskeletal pain (bone, muscle or joint)</p></td><td style="vertical-align:top; width:111px"><p>4.1</p></td><td style="vertical-align:top"><p>2.5</p></td></tr><tr><td style="vertical-align:top; width:331px"><p>Muscle cramp</p></td><td style="vertical-align:top; width:111px"><p>0.0</p></td><td style="vertical-align:top"><p>1.0</p></td></tr><tr><td style="vertical-align:top; width:331px"><p><strong>Nervous System/Psychiatric</strong></p></td><td style="vertical-align:top; width:111px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:331px"><p>Headache</p></td><td style="vertical-align:top; width:111px"><p>2.6</p></td><td style="vertical-align:top"><p>1.5</p></td></tr><tr><td style="vertical-align:top; width:331px"><p>Dizziness</p></td><td style="vertical-align:top; width:111px"><p>0.0</p></td><td style="vertical-align:top"><p>1.0</p></td></tr><tr><td style="vertical-align:top; width:331px"><p><strong>Special Senses</strong></p></td><td style="vertical-align:top; width:111px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:331px"><p>Taste Perversion</p></td><td style="vertical-align:top; width:111px"><p>0.5</p></td><td style="vertical-align:top"><p>1.0</p></td></tr></tbody></table><p>* Considered possibly, probably, or definitely drug-related as assessed by the investigators.</p><p>&nbsp;</p><p>One patient treated with alendronate (10 mg/day), who had a history of peptic ulcer disease and gastrectomy and who was taking concomitant acetylsalicylic acid (ASA) developed an anastomotic ulcer with mild hemorrhage, which was considered drug-related. &nbsp;ASA and alendronate were discontinued and the patient recovered.</p><p>In the two-year extension (treatment years 4 and 5) of the above studies, the overall safety profile of alendronate 10 mg/day was similar to that observed during the three-year placebo-controlled period. &nbsp;Additionally, the proportion of patients who discontinued alendronate 10 mg/day due to any clinical adverse experience was similar to that during the first three years of the study.</p><p>In the Fracture Intervention Trial, discontinuation of therapy due to any clinical adverse experience occurred in 9.1% of 3236 patients treated with alendronate 5 mg/day for two years and 10 mg/day for either one or two additional years and 10.1% of 3223 patients treated with placebo. &nbsp;Discontinuations due to upper gastrointestinal adverse experiences were: alendronate, 3.2%; placebo, 2.7%. The overall adverse experience profile was similar to that seen in other studies with alendronate 5 or 10 mg/day.</p><p>In a one-year, double-blind multicenter study, the overall safety and tolerability profiles of alendronate 70 mg once weekly and alendronate 10 mg daily were similar. &nbsp;The adverse experiences considered by the investigators as possibly, probably, or definitely drug-related in&nbsp;<strong><u>&gt;</u></strong>1% of patients in either treatment group are presented in the following table:</p><p>&nbsp;</p><p><strong>Drug-Related* Adverse Experiences Reported in <u>&gt; </u>1 % of Patients<strong> </strong>Treated for Osteoporosis</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top" rowspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Alendronate</strong></p><p><strong>70 mg Once weekly</strong></p><p><strong>%</strong></p><p><strong>(n</strong><strong> </strong><strong>= 519)</strong></p></td><td style="vertical-align:top"><p><strong>Alendronate </strong></p><p><strong>10mg/day</strong></p><p><strong>%</strong></p><p><strong>(n</strong><strong> </strong><strong>= 370)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>3.7</p></td><td style="vertical-align:top"><p>3.0</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>2.7</p></td><td style="vertical-align:top"><p>2.2</p></td></tr><tr><td style="vertical-align:top"><p>Acid regurgitation</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>2.4</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>2.4</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal distention</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>1.4</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>1.6</p></td></tr><tr><td style="vertical-align:top"><p>Flatulence</p></td><td style="vertical-align:top"><p>0.4</p></td><td style="vertical-align:top"><p>1.6</p></td></tr><tr><td style="vertical-align:top"><p>Gastritis</p></td><td style="vertical-align:top"><p>0.2</p></td><td style="vertical-align:top"><p>1.1</p></td></tr><tr><td style="vertical-align:top"><p>Gastric ulcer</p></td><td style="vertical-align:top"><p>0.0</p></td><td style="vertical-align:top"><p>1.1</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal pain (bone, muscle or joint)</p></td><td style="vertical-align:top"><p>2.9</p></td><td style="vertical-align:top"><p>3.2</p></td></tr><tr><td style="vertical-align:top"><p>Muscle cramp</p></td><td style="vertical-align:top"><p>0.2</p></td><td style="vertical-align:top"><p>1.1</p></td></tr></tbody></table><p>* Considered possibly, probably, or definitely drug-related as assessed by the investigators.</p><p>&nbsp;</p><p><strong>Men</strong></p><p>In two, placebo-controlled, double-blind, multicenter studies in men (a two-year study of alendronate 10 mg/day (n=146) and a one-year study of alendronate 70 mg once weekly&nbsp;(n=109)), the safety profile of alendronate was generally similar to that seen in postmenopausal women. The rates of discontinuation of therapy due to any clinical adverse experience were 2.7% for alendronate 10 mg/day vs 10.5% for placebo and 6.4% for alendronate 70 mg once weekly vs 8.6% for placebo.</p><p>&nbsp;</p><p><strong>Other Studies in Men and Women</strong></p><p>In a ten-week endoscopy study in men and women (n <strong>= </strong>277; mean age: 55) no difference was seen in upper gastrointestinal tract lesions between alendronate 70 mg once weekly and placebo.</p><p>In an additional one-year study in men and women (n <strong>= </strong>335; mean age: 50) the overall safety and tolerability profiles of alendronate 70 mg once weekly were similar to that of placebo and no difference was seen between men and women.</p><p>&nbsp;</p><p><strong>Prevention of Osteoporosis in Postmenopausal Women</strong></p><p>The safety of alendronate 5 mg/day in postmenopausal women 40-60 years of age has been evaluated in three double-blind, placebo-controlled studies involving over 1400 patients randomized to receive alendronate for either two or three years. &nbsp;In these studies the overall safety profiles of alendronate 5 mg/day and placebo were similar. &nbsp;Discontinuation of therapy due to any clinical adverse experience occurred in 7.5% of 642 patients treated with alendronate 5 mg/day and 5.7% of 648 patients treated with placebo. &nbsp;Adverse experiences reported by the investigators as possibly, probably or definitely drug-related in <u>&gt; </u>1 % of patients treated with either alendronate 5 mg/day or placebo are presented in the following table:</p><p>&nbsp;</p><p><strong>Drug-Related* Adverse Experiences Reported in <u>&gt; </u>1 % of Patients<strong> </strong>Treated for Osteoporosis</strong></p><table style="width:355px" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:96px" rowspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:258px"><p><strong>Alendronate</strong></p><p><strong>5 mg/day</strong></p><p><strong>%</strong></p><p><strong>(n</strong><strong> </strong><strong>= 642)</strong></p></td><td style="vertical-align:top; width:200px"><p><strong>Placebo</strong></p><p><strong>%</strong></p><p><strong>(n</strong><strong> </strong><strong>= 648)</strong></p></td></tr><tr><td style="vertical-align:top; width:96px"><p><strong>Gastrointestinal</strong></p></td><td style="vertical-align:top; width:258px"><p>&nbsp;</p></td><td style="vertical-align:top; width:1px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:96px"><p>Abdominal pain</p></td><td style="vertical-align:top; width:258px"><p>1.7</p></td><td style="vertical-align:top; width:1px"><p>3.4</p></td></tr><tr><td style="vertical-align:top; width:96px"><p>Acid regurgitation</p></td><td style="vertical-align:top; width:258px"><p>1.4</p></td><td style="vertical-align:top; width:1px"><p>2.5</p></td></tr><tr><td style="vertical-align:top; width:96px"><p>Diarrhea</p></td><td style="vertical-align:top; width:258px"><p>1.1</p></td><td style="vertical-align:top; width:1px"><p>1.7</p></td></tr><tr><td style="vertical-align:top; width:96px"><p>Dyspepsia</p></td><td style="vertical-align:top; width:258px"><p>1.9</p></td><td style="vertical-align:top; width:1px"><p>1.7</p></td></tr><tr><td style="vertical-align:top; width:96px"><p>Nausea</p></td><td style="vertical-align:top; width:258px"><p>1.4</p></td><td style="vertical-align:top; width:1px"><p>1.4</p></td></tr></tbody></table><p>* Considered possibly, probably, or definitely drug-related as assessed by the investigators.</p><p>&nbsp;</p><p><strong>Concomitant Use with Estrogen/Hormone Replacement Therapy</strong></p><p>In two studies (of one and two years&rsquo; duration) of postmenopausal osteoporotic women (total: n=853), the safety and tolerability profile of combined treatment with alendronate 10 mg once daily and estrogen &plusmn; progestin (n=354) was consistent with those of the individual treatments.</p><p>&nbsp;</p><p><strong>Treatment and Prevention of Glucocorticoid-Induced Osteoporosis</strong></p><p>In two, one-year, placebo-controlled, double-blind, multicenter studies in patients receiving glucocorticoid treatment, the overall safety and tolerability profiles of alendronate 5 or 10 mg/day were generally similar to that of placebo. &nbsp;Adverse experiences reported by the investigators as possibly, probably or definitely drug-related in <u>&gt; </u>1 % of patients treated with either alendronate 5 or 10 mg/day or placebo are presented in the following table:</p><p>&nbsp;</p><p><strong>Drug-Related* Adverse Experiences</strong><strong> </strong><strong>Reported in <u>&gt; </u>1 % of Patients </strong></p><p><strong>Treatment and Prevention of Glucocorticoid-Induced Osteoporosis</strong></p><table style="width:562px" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:179px" rowspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:66px"><p><strong>Alendronate</strong></p><p><strong>10 mg/day</strong></p><p><strong>%</strong></p><p><strong>(n</strong><strong> </strong><strong>= 157)</strong></p></td><td style="vertical-align:top; width:139px"><p><strong>Alendronate</strong></p><p><strong>5 mg/day</strong></p><p><strong>%</strong></p><p><strong>(n</strong><strong> </strong><strong>= 161)</strong></p></td><td style="vertical-align:top; width:118px"><p><strong>Placebo</strong></p><p><strong>%</strong></p><p><strong>(n</strong><strong> </strong><strong>= 159)</strong></p></td></tr><tr><td style="vertical-align:top; width:179px"><p><strong>Gastrointestinal</strong></p></td><td style="vertical-align:top; width:66px"><p>&nbsp;</p></td><td style="vertical-align:top; width:139px"><p>&nbsp;</p></td><td style="vertical-align:top; width:118px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:179px"><p>Abdominal pain</p></td><td style="vertical-align:top; width:66px"><p>3.2</p></td><td style="text-align:left; vertical-align:bottom; width:139px"><p>1.9</p></td><td style="vertical-align:top; width:118px"><p>0.0</p></td></tr><tr><td style="vertical-align:top; width:179px"><p>Acid regurgitation</p></td><td style="vertical-align:top; width:66px"><p>2.5</p></td><td style="text-align:left; vertical-align:bottom; width:139px"><p>1.9</p></td><td style="vertical-align:top; width:118px"><p>1.3</p></td></tr><tr><td style="vertical-align:top; width:179px"><p>Constipation</p></td><td style="vertical-align:top; width:66px"><p>1.3</p></td><td style="text-align:left; vertical-align:bottom; width:139px"><p>0.6</p></td><td style="vertical-align:top; width:118px"><p>0.0</p></td></tr><tr><td style="vertical-align:top; width:179px"><p>Melena</p></td><td style="vertical-align:top; width:66px"><p>1.3</p></td><td style="text-align:left; vertical-align:bottom; width:139px"><p>0.0</p></td><td style="vertical-align:top; width:118px"><p>0.0</p></td></tr><tr><td style="vertical-align:top; width:179px"><p>Nausea</p></td><td style="vertical-align:top; width:66px"><p>0.6</p></td><td style="text-align:left; vertical-align:bottom; width:139px"><p>1.2</p></td><td style="vertical-align:top; width:118px"><p>0.6</p></td></tr></tbody></table><table style="width:561px" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:190px"><p>Diarrhea</p></td><td style="text-align:left; vertical-align:bottom; width:95px"><p>0.0</p></td><td style="text-align:left; vertical-align:bottom; width:148px"><p>0.0</p></td><td style="text-align:left; vertical-align:bottom; width:125px"><p>1.3</p></td></tr><tr><td style="text-align:left; vertical-align:bottom; width:190px"><p><strong>Nervous System/Psychiatric</strong></p></td><td style="text-align:left; vertical-align:bottom; width:95px"><p>&nbsp;</p></td><td style="text-align:left; vertical-align:bottom; width:148px"><p>&nbsp;</p></td><td style="text-align:left; vertical-align:bottom; width:125px"><p>&nbsp;</p></td></tr><tr><td style="text-align:left; vertical-align:bottom; width:190px"><p>Headache</p></td><td style="text-align:left; vertical-align:bottom; width:95px"><p>0.6</p></td><td style="text-align:left; vertical-align:bottom; width:148px"><p>0.0</p></td><td style="text-align:left; vertical-align:bottom; width:125px"><p>1.3</p></td></tr></tbody></table><p>* Considered possibly, probably, or definitely drug-related as assessed by the investigators.</p><p>The overall safety and tolerability profile in the glucocorticoid-induced osteoporosis population that continued therapy for the second year of the studies was consistent with that observed in the first year.</p><p>&nbsp;</p><p><strong>Paget&rsquo;s disease of Bone</strong></p><p>In clinical studies (Paget&rsquo;s disease and osteoporosis), adverse experiences reported in 175 patients taking alendronate 40 mg/day for 3 -12 months were similar to those in postmenopausal women treated with alendronate 10 mg/day. &nbsp;However, there was an apparent increased incidence of upper gastrointestinal adverse experiences in patients taking alendronate 40 mg/day (17.7% alendronate vs 10.2% placebo). &nbsp;Isolated cases of esophagitis and gastritis resulted in discontinuation of treatment.</p><p>Additionally, musculoskeletal pain (bone, muscle or joint), which has been described in patients with Paget&rsquo;s disease treated with other bisphosphonates, was reported by the investigators as possibly, probably, or definitely drug-related in approximately 6% of patients treated with alendronate 40 mg/day versus approximately 1% of patients treated with placebo, but rarely resulted in discontinuation of therapy. &nbsp;Discontinuation of therapy due to any clinical adverse experience occurred in 6.4% of patients with Paget&rsquo;s disease treated with alendronate 40 mg/day and 2.4% of patients treated with placebo.</p><p>&nbsp;</p><p><strong><u>Less</u></strong><strong><u> </u></strong><strong><u>Common</u></strong><strong><u> </u></strong><strong><u>Clinical</u></strong><strong><u> Trial Adverse Drug Reactions (&lt;1%)</u></strong><strong> </strong></p><p><strong>Skin:</strong><strong> </strong>Rarely, rash and erythema have occurred.</p><p>&nbsp;</p><p><strong><u>A</u><u>bn</u><u>o</u><u>r</u><u>m</u><u>a</u><u>l Hematologic and Clinical Chemistry Findings</u></strong></p><p><strong>Laboratory</strong><strong> </strong><strong>Tests</strong></p><p>In double-blind, multicenter, controlled studies, asymptomatic, mild, and transient decreases in serum calcium and phosphate were observed in approximately 18 and 10%, respectively, of patients taking alendronate versus approximately 12 and 3% of those taking placebo. However, the incidences of decreases in serum calcium to &lt; 8.0 mg/dL (2.0 mM) and serum phosphate to &le; 2.0 mg P*/dL(0.65 mM) were similar in both treatment groups.</p><p>&nbsp;</p><p>In a small, open-label study, at higher doses (80 mg/day) some patients had elevated transaminases. However, this was not observed at 40 mg/day. No clinically significant toxicity was associated with these laboratory abnormalities.</p><p>Rare cases of leukemia have been reported following therapy with other bisphosphonates.</p><p>Any causal relationship to either the treatment or to the patients&#39; underlying disease has not been established.</p><p>*P: Elemental phosphorus</p><p>&nbsp;</p><p><strong><u>P</u><u>o</u><u>st</u><u>-</u><u>Market Adverse Drug Reactions</u></strong></p><p><strong>Post-Marketing</strong><strong> </strong><strong>Experience</strong></p><p>The following adverse reactions have been reported in post-marketing use:</p><p><strong>Body as a Whole: </strong>Hypersensitivity reactions including urticaria and rarely angioedema. &nbsp;As &nbsp;&nbsp;with other bisphosphonates, transient symptoms as in an acute-phase response (myalgia, malaise, asthenia and rarely, fever) have been reported with alendronate, typically in association with initiation of treatment. &nbsp;Rarely, symptomatic hypocalcemia has occurred, both in association with predisposing conditions and in patients without known predisposing conditions. Rarely, peripheral edema.</p><p><strong>Dental: </strong>Localized osteonecrosis of the jaw (ONJ) has been reported rarely with oral bisphosphonate treatment. ONJ is generally associated with local infection (including osteomyelitis), tooth extraction with delayed healing (see WARNINGS AND PRECAUTIONS, General).</p><p><strong>Gastrointestinal: </strong>Esophagitis, esophageal erosions, esophageal ulcers, rarely esophageal &nbsp;stricture or perforation, and oropharyngeal ulceration. &nbsp;Some of these have been serious and required hospitalization. &nbsp;Rarely, gastric or duodenal ulcers, some severe and with complications. (see WARNINGS AND PRECAUTIONS and DOSAGE AND ADMINISTRATION).</p><p><strong>Musculoskeletal: </strong>bone, joint, and/or muscle pain, rarely severe and/or incapacitating (see WARNINGS AND PRECAUTIONS); joint swelling; low-energy femoral shaft fracture (see WARNINGS AND PRECAUTIONS).</p><p><strong>Nervous System: </strong>Dizziness, vertigo, dysgeusia.</p><p><strong>Skin: &nbsp;</strong>Rash (occasionally with photosensitivity), pruritus, alopecia, rarely severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.</p><p><strong>Special</strong><strong> Senses: </strong>Rarely uveitis, scleritis or episcleritis.</p><p>&nbsp;</p><p><strong>-&nbsp; To report any side effect(s):</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Saudi Arabia:</em></strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><ul><li>Fax: +966‐11‐205‐7662</li><li>Call NPC at +966‐11‐2038222, Exts: 2317‐2356‐2353‐2354‐2334‐2340.</li><li>Toll free phone: 8002490000</li><li>E‐mail: npc.drug@sfda.gov.sa</li><li>Website: www.sfda.gov.sa/npc</li></ul><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Other</em></strong><strong><em> </em></strong><strong><em>GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific information is available on the treatment of overdosage with ALENDOCAN (alendronate sodium). &nbsp;Hypocalcemia, hypophosphatemia, and upper gastrointestinal adverse events, such as upset stomach, heartburn, esophagitis, gastritis, or ulcer, may result from oral overdosage. &nbsp;Milk or antacids should be given to bind alendronate. &nbsp;Due to the risk of esophageal irritation, vomiting should not be induced and the patient should remain fully upright.</p><p>Dialysis would not be beneficial.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>For management of a suspected drug overdose, contact your regional Poison Control Centre immediately.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong>Alendronate is a bisphosphonate that binds to bone hydroxyapatite and specifically inhibits the activity of osteoclasts, the bone-resorbing cells. Alendronate reduces bone resorption with no direct effect on bone formation, although the latter process is ultimately reduced because bone resorption and formation are coupled during bone turnover.</p><p>&nbsp;</p><p><strong>Osteoporosis in Postmenopausal Women</strong></p><p>Osteoporosis is characterized by low bone mass that leads to an increased risk of fracture. The diagnosis can be confirmed by the finding of low bone mass, evidence of fracture on xray, a history of osteoporotic fracture, or height loss or kyphosis, indicative of vertebral fracture.</p><p>Osteoporosis occurs in both males and females but is most common among women following the menopause, when bone turnover increases and the rate of bone resorption exceeds that of bone formation. These changes result in progressive bone loss and lead to osteoporosis in a significant proportion of women over age 50. Fractures, usually of the spine, hip, and wrist, are the common consequences. From age 50 to age 90, the risk of hip fracture in white women increases 50-fold and the risk of vertebral fracture 15- to 30-fold. It is estimated that approximately 40% of 50-year-old women will sustain one or more osteoporosis-related fractures of the spine, hip, or wrist during their remaining lifetimes. Hip fractures, in particular, are associated with substantial morbidity, disability, and mortality.</p><p>&nbsp;</p><p>Daily oral doses of alendronate (5, 20, and 40 mg for six weeks) in postmenopausal women produced biochemical changes indicative of dose-dependent inhibition of bone resorption, including decreases in urinary calcium and urinary markers of bone collagen degradation (such as deoxypyridinoline and cross-linked N-telopeptides of type I collagen). These biochemical changes tended to return toward baseline values as early as 3 weeks following the discontinuation of therapy with alendronate and did not differ from placebo after 7 months.</p><p>&nbsp;</p><p>Long-term treatment of osteoporosis with alendronate 10 mg/day (for up to five years) reduced urinary excretion of markers of bone resorption, deoxypyridinoline and crosslinked N-telopeptides of type I collagen, by approximately 50% and 70%, respectively, to reach levels similar to those seen in healthy premenopausal women. Similar decreases were seen in patients &nbsp;in osteoporosis prevention studies who received alendronate 5 mg/day. The decrease in the rate of bone resorption indicated by these markers was evident as early as one month and at three to six months reached a plateau that was maintained for the entire duration of treatment with alendronate. In osteoporosis treatment studies, alendronate 10 mg/day decreased the markers of bone formation, osteocalcin and bone specific alkaline phosphatase by approximately 50%, and total serum alkaline phosphatase, by approximately 25 to 30%, to reach a plateau after 6 to 12 months. In osteoporosis prevention studies, alendronate 5 mg/day decreased osteocalcin and total serum alkaline phosphatase by approximately 40% and 15%, respectively. Similar reductions in the rate of bone turnover were observed in postmenopausal women during a one-year study with alendronate 70 mg once weekly for the treatment of osteoporosis. These data indicate that the &nbsp;rate of bone turnover reached a new steady-state, despite the progressive increase in the total amount of alendronate deposited within bone.</p><p>&nbsp;</p><p>As a result of inhibition of bone resorption, asymptomatic reductions in serum calcium and phosphate concentrations were also observed following treatment with alendronate. In the long- term studies, reductions from baseline in serum calcium (approximately 2%) and phosphate (approximately 4 to 6%) were evident the first month after the initiation of alendronate 10 mg. No further decreases in serum calcium were observed for the five year duration of treatment, however, serum phosphate returned toward prestudy levels during years three through five.</p><p>Similar reductions were observed with alendronate 5 mg/day. In a one-year study with alendronate 70 mg once weekly, similar reductions were observed at 6 and 12 months. The reduction in serum phosphate may reflect not only the positive bone mineral balance due to alendronate but also a decrease in renal phosphate reabsorption.</p><p>&nbsp;</p><p><strong>Osteoporosis in Men</strong></p><p>Even though osteoporosis is less prevalent in men than in postmenopausal women, a significant proportion of osteoporotic fractures occur in men. The prevalence of vertebral deformities appears to be similar in men and women. Treatment of men with osteoporosis with alendronate 10 mg/day for two years reduced urinary excretion of cross-linked N-telopeptides of type I collagen by approximately 60% and bone-specific alkaline phosphatase by approximately 40%.</p><p>&nbsp;</p><p>Similar reductions were observed in a one-year study in men with osteoporosis receiving alendronate 70 mg once weekly.</p><p>&nbsp;</p><p><strong>Glucocorticoid-Induced Osteoporosis</strong></p><p>Sustained use of glucocorticoids is commonly associated with development of osteoporosis and resulting fractures (especially vertebral, hip, and rib). It occurs both in males and females of all ages. Osteoporosis occurs as a result of inhibited bone formation and increased bone resorption resulting in net bone loss. Alendronate decreases bone resorption without directly inhibiting bone formation.</p><p>&nbsp;</p><p>In clinical studies of up to two years&rsquo; duration, alendronate 5 and 10 mg/day reduced cross-linked N-telopeptides of type 1 collagen (a marker of bone resorption) by approximately 60% &nbsp;and reduced bone-specific alkaline phosphatase and total serum alkaline phosphatase (markers of bone formation) by approximately 15 to 30% and 8 to 18%, respectively. As a result of inhibition of bone resorption, alendronate 5 and 10 mg/day induced asymptomatic decreases in serum calcium (approximately 1 to 2%) and serum phosphate (approximately 1 to 8%).</p><p>&nbsp;</p><p><strong>Paget&#39;s Disease of Bone</strong></p><p>Paget&#39;s disease of bone is a chronic, focal skeletal disorder characterized by greatly increased and disorderly bone remodeling. Excessive osteoclastic bone resorption is followed by osteoblastic new bone formation, leading to the replacement of the normal bone architecture by disorganized, enlarged, and weakened bone structure.</p><p>&nbsp;</p><p>Clinical manifestations of Paget&#39;s disease range from no symptoms to severe morbidity due to bone pain, bone deformity, pathological fractures, and neurological and other complications. Serum alkaline phosphatase, the most frequently used biochemical index of disease activity, provides an objective measure of disease severity and response to therapy.</p><p>&nbsp;</p><p>Alendronate decreases the rate of bone resorption directly, which leads to an indirect decrease in bone formation. In clinical trials, alendronate 40 mg once daily for six months produced significant decreases in serum alkaline phosphatase as well as in urinary markers of bone collagen degradation. As a result of the inhibition of bone resorption, alendronate induced generally mild, transient, and asymptomatic decreases in serum calcium and phosphate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of Pharmacokinetic Parameters in the Normal Population</strong></p><p><strong>&nbsp;&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Mean</strong></p></td><td style="vertical-align:top"><p><strong>90% Confidence Interval</strong></p></td></tr><tr><td style="vertical-align:top"><p>Absolute bioavailability of 5 mg tablet, taken 2 hours before first meal of the day</p></td><td style="vertical-align:top"><p>0.63% (females)</p></td><td style="vertical-align:top"><p>(0.48, 0.83)</p></td></tr><tr><td style="vertical-align:top" rowspan="2"><p>Absolute bioavailability of 10 mg tablet, taken 2 hours before first meal of the day</p></td><td style="vertical-align:top"><p>0.78% (females)</p></td><td style="vertical-align:top"><p>(0.61, 1.04)</p></td></tr><tr><td style="vertical-align:top"><p>0.59% (males)</p></td><td style="vertical-align:top"><p>(0.43, 0.81)</p></td></tr></tbody></table><table style="width:743px" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:473px"><p>Absolute bioavailability of 40 mg tablet, taken 2 hours before first meal of the day</p></td><td style="vertical-align:top; width:111px"><p>0.60%</p><p>(females)</p></td><td style="vertical-align:top; width:156px"><p>(0.46, 0.78)</p></td></tr><tr><td style="vertical-align:top; width:473px"><p>Absolute bioavailability of 70 mg tablet, taken 2 hours before first meal of the day</p></td><td style="vertical-align:top; width:111px"><p>0.57%</p><p>(females)</p></td><td style="vertical-align:top; width:156px"><p>(0.44, 0.73)</p></td></tr><tr><td style="vertical-align:top; width:473px"><p>Renal Clearance mL/s (mL/min) (n=6)</p></td><td style="vertical-align:top; width:111px"><p>1.18</p><p>(71)</p></td><td style="vertical-align:top; width:156px"><p>(1.07, 1.3)</p><p>(64, 78)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Absorption:</strong></p><p>Relative to an intravenous (IV) reference dose, the mean oral bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardized breakfast. &nbsp;Oral bioavailability of the 10 mg tablet in men was 0.59%.</p><p>A study examining the effect of timing of a meal on the bioavailability of alendronate was performed in 49 postmenopausal women. &nbsp;Bioavailability was decreased (by approximately 40%) when 10 mg alendronate was administered either 0.5 or 1 hour before a standardized breakfast, when compared to dosing 2 hours before eating. &nbsp;In studies of treatment and prevention of osteoporosis, alendronate was effective when administered at least 30 minutes before breakfast.</p><p>Bioavailability was negligible whether alendronate was administered with or up to two hours after a standardized breakfast. &nbsp;Concomitant administration of alendronate with coffee or orange juice reduced bioavailability by approximately 60%.</p><p>In healthy subjects, oral prednisone (20 mg three times daily for five days) did not produce a clinically meaningful change in the oral bioavailability of alendronate (a mean increase ranging from 20 to 44%).</p><p>&nbsp;</p><p><strong>Distribution:</strong></p><p>Preclinical studies (in male rats) show that alendronate transiently distributes to soft tissues following 1 mg/kg IV administration but is then rapidly redistributed to bone or excreted in the urine. &nbsp;The mean steady-state volume of distribution, exclusive of bone, is at least 28 L in humans. &nbsp;Concentrations of drug in plasma following therapeutic oral doses are too low (less than 5 ng/mL) for analytical detection. &nbsp;Protein binding in human plasma is approximately 78%.</p><p>&nbsp;</p><p><strong>Metabolism:</strong></p><p>There is no evidence that alendronate is metabolized in animals or humans.</p><p>&nbsp;</p><p><strong>Excretion:</strong></p><p>Following a single IV dose of [14C] alendronate, approximately 50% of the radioactivity was excreted in the urine within 72 hours and little or no radioactivity was recovered in the feces. Following a single 10 mg IV dose, the renal clearance of alendronate was 71 mL/min and systemic clearance did not exceed 200 mL/min. &nbsp;Plasma concentrations fell by more than 95% within 6 hours following IV administration. &nbsp;The terminal half-life in humans is estimated to exceed 10 years, probably reflecting release of alendronate from the skeleton. &nbsp;Based on the above, it is estimated that after 10 years of oral treatment with alendronate (10 mg daily), the amount of alendronate released daily from the skeleton is approximately 25% of that absorbed from the gastrointestinal tract.</p><p>&nbsp;</p><p><strong><u>Special Populations and Conditions</u></strong></p><p><strong>Pediatrics:</strong></p><p>The oral bioavailability in children (4 to 16 years of age) with osteogenesis imperfecta (OI) was similar to that observed in adults; however, alendronate is not indicated for use in children (see WARNINGS AND PRECAUTIONS, Special Populations, Pediatrics).</p><p>&nbsp;</p><p><strong>Geriatrics:</strong></p><p>Bioavailability and disposition (urinary excretion) were similar in elderly (<u>&gt;</u><u> </u>65 years of age) and younger patients. &nbsp;No dosage adjustment is necessary (see DOSAGE AND ADMINISTRATION).</p><p>&nbsp;</p><p><strong>Gender:</strong></p><p>Bioavailability and the fraction of an IV dose excreted in urine were similar in men and women.</p><p>&nbsp;</p><p><strong>Race:</strong></p><p>Pharmacokinetic differences due to race have not been studied.</p><p>&nbsp;</p><p><strong>Hepatic Insufficiency:</strong></p><p>As there is evidence that alendronate is not metabolized or excreted in the bile, no studies were conducted in patients with hepatic insufficiency. &nbsp;No dosage adjustment is necessary.</p><p>&nbsp;</p><p><strong>Renal Insufficiency:</strong></p><p>Preclinical studies show that, in rats with kidney failure, increasing amounts of drug are present in plasma, kidney, spleen, and tibia. &nbsp;In healthy controls, drug that is not deposited in bone is rapidly excreted in the urine. &nbsp;No evidence of saturation of bone uptake was found after 3 weeks dosing with cumulative IV doses of 35 mg/kg in young male rats. &nbsp;Although no clinical information is available, it is likely that, as in animals, elimination of alendronate via the kidney will be reduced in patients with impaired renal function. &nbsp;Therefore, somewhat greater accumulation of alendronate in bone might be expected in patients with impaired renal function.</p><p>No dosage adjustment is necessary for patients with mild-to-moderate renal insufficiency (creatinine clearance 0.58 to 1 mL/s [35 to 60 mL/min]). &nbsp;ALENDOCAN is not recommended for patients with more severe renal insufficiency (creatinine clearance <strong>&lt; </strong>0.58 mL/s [&lt;35 mL/min]) due to lack of experience.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Acute Toxicity</strong></p><p>The oral LD50 values of alendronate in female rats and mice were 552 mg/kg (3256 mg/m2) and 966 mg/kg (2898 mg/m2) (equivalent to human oral doses*&nbsp;of 27,600 and 48,300 mg), respectively. In males, these values were slightly higher, 626 and 1280 mg/kg, respectively. There was no lethality in dogs at oral doses up to 200 mg/kg (4000 mg/m2&nbsp;(equivalent to a human oral dose* of 10,000 mg).</p><p>&nbsp;</p><p><strong>Chronic Toxicity</strong></p><p>Alendronate-related changes in the repeated dose-toxicity studies of up to one year in rats and three years in dogs consisted of retention of primary spongiosa of bone in areas of endochondral bone formation, sustained reduction of alkaline phosphatase activities, and transient reduction in serum calcium and phosphate concentrations. &nbsp;These are related to the desired pharmacologic activity of alendronate. &nbsp;The species most sensitive to nephrotoxicity (dogs) required a dose* equivalent to at least 100 mg in humans to manifest nephrotoxicity. Rats also showed evidence of this effect at higher doses. &nbsp;Gastrointestinal toxicity was seen in rodents only. &nbsp;This appears to be due to a direct effect on the mucosa and occurred only at doses greater than 2.5 mg/kg/day.</p><p>&nbsp;</p><p><strong>Carcinogenicity</strong></p><p>No evidence of carcinogenic effect was observed in a 105-week study in rats receiving oral doses up to 3.75 mg/kg/day and in a 92-week study in mice receiving oral doses up to 10 mg/kg/day.</p><p>Harderian gland (a retroorbital gland not present in humans) adenomas were increased in high- dose female mice (p <strong>= </strong>0.003) in a 92-week carcinogenicity study at doses of alendronate of 1, 3 and 10 mg/kg/day (males) or 1, 2 and 5 mg/kg/day (females). These doses are equivalent to 0.5 to 4 times the 10 mg human dose based on surface area, mg/m2.</p><p>Parafollicular cell (thyroid) adenomas were increased in high-dose male rats &nbsp;(p <strong>= </strong>0.003) in a 2- year carcinogenicity study at doses of 1 and 3.75 mg/kg body weight. &nbsp;These doses are equivalent to 1 and 3 times the 10 mg human dose based on surface area.</p><p>&nbsp;</p><p><strong>Mutagenesis</strong></p><p>Alendronate was not genotoxic in the <em>in vitro </em>microbial mutagenesis assay with and without metabolic activation. &nbsp;Similarly, no evidence of mutagenicity was observed in an <em>in vitro </em>mammalian cell mutagenesis assay, an <em>in vitro </em>alkaline elution assay in rat hepatocytes, and an <em>in</em><em> vivo </em>chromosomal aberration assay in mice at IV doses up to 25 mg/kg/day (75 mg/m2). &nbsp;In an <em>in</em><em> vitro </em>chromosomal aberration assay in Chinese hamster ovary cells, however, alendronate was weakly positive at concentrations <u>&gt; </u>5 mM in the presence of cytotoxicity. &nbsp;This is of no relevance to safety in humans since similar concentrations are not achievable <em>in vivo </em>at therapeutic doses. &nbsp;Furthermore, clear negative results in four of five genotoxicity studies, including the most relevant studies for human carcinogenic potential (the <em>in vivo </em>chromosomal aberration assay and the microbial mutagenesis assay), and negative carcinogenicity studies in rats and mice lead to the conclusion that there is no evidence of genotoxic or carcinogenic risks from alendronate in humans.</p><p>&nbsp;</p><p><strong>Reproduction</strong></p><p>Alendronate had no effect on fertility or reproductive performance (male or female) in rats at &nbsp;oral doses up to 5 mg/kg/day. &nbsp;The only drug-related effect seen in these studies was difficulty in parturition in rats, which is directly related to pharmacologically mediated hypocalcemia. &nbsp;This effect can be prevented in rats by calcium supplementation. &nbsp;Furthermore, a clear no-effect level of 1.25 mg/kg/day was established.</p><p>&nbsp;</p><p><strong>Development</strong></p><p>In developmental toxicity studies, there were no adverse effects at doses up to 25 mg/kg/day in rats and 35 mg/kg/day in rabbits.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Name</strong><strong> </strong><strong>of the excipients(s)</strong></p></td></tr><tr><td style="vertical-align:top"><p>magnesium stearate</p></td></tr><tr><td style="vertical-align:top"><p>mannitol</p></td></tr><tr><td style="vertical-align:top"><p>microcrystalline cellulose</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C and keep out of reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Primary packaging:</strong></p><p>Blister</p><p><strong>Secondary packaging:</strong></p><p>Carton</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>If your doctor or pharmacist tells you to stop taking this medicine or it has passed its expiry date, your pharmacist can dispose of the remaining medicine safely.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apotex Inc., 150 Signet Toronto, Ontario, M9L 1T9 Canada.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                04/2017.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>